The Alzheimer's Disease Neuroimaging Initiative (ADNI) study protocol currently precludes disclosure of test results to participants. A survey among ADNI investigators, however, demonstrates that most want this policy changed, in light of the approval of 18F-florbetapir as a PET amyloid ligand. Should we tell the study participants if they want to know?
- Serge Gauthier
- Pedro Rosa-Neto
